Latest News for: diffusivity

Edit

Analysis of a progressive diffuse intrinsic pontine glioma: a case report - Children's National (Children's National Medical Center Inc)

Public Technologies 28 Aug 2025
Despite multiple clinical trials testing an assortment of new treatments, the survival rate for diffuse intrinsic pontine glioma (DIPG) remains abysmal, with most children succumbing to the pediatric brainstem tumor within 12 months of diagnosis.
Edit

Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma - Children's National (Children's National Medical Center Inc)

Public Technologies 28 Aug 2025
Needle biopsies help to guide diagnosis and targeted therapies for diffuse intrinsic pontine gliomas (DIPGs), which make up 10 percent to 15 percent of all pediatric brain tumors but carry a median survival of 9 to 12 months.
Edit

Mark Zuckerberg gifts noise-canceling headphones to his Palo Alto neighbors as a peace offering to diffuse tension

The Times of India 27 Aug 2025
Meta CEO Mark Zuckerberg has reportedly gifted noise-cancelling headphones to his neighbours in Palo Alto ... He had also gifted bottles of sparkling wine and boxes of Krispy Kreme doughnuts. But, none of them have been effective.
Edit

BROADPEAK SA: Telenor s'associe à Broadpeak pour la diffusion multi-pays de contenus vidéo (Broadpeak SA)

Public Technologies 27 Aug 2025
Telenor s'associe à Broadpeak pour la diffusion multi-pays de contenus vidéo 27-Aou-2025 / 17.45 CET/CEST Information réglementaire transmise par EQS Group.
Edit

Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | DelveInsight

PR Newswire 27 Aug 2025
The diffuse large B-cell lymphoma (DLBCL) market size was USD 4.7 billion in the leading markets (the US, EU4, UK, and Japan) in 2024 ... Key Factors Driving the Growth of Diffuse Large B-cell Lymphoma Market  ... Diffuse Large B-cell Lymphoma Market.
Edit

Diffuse Midline Glioma Treatment Landscape: FDA Approves MODEYSO, First Targeted Therapy for H3 K27M-Mutant Tumors ...

GetNews 26 Aug 2025
Key Diffuse Midline Glioma Market Highlights. MODEYSO's FDA approval is expected to be a key diffuse midline glioma market driver, given its first-in-class status as a targeted therapy for H3 K27M-mutant tumors ... Diffuse Midline Glioma Companies.
Edit

Controlling transient and coupled diffusion with pseudoconformal mapping

PNAS 07 Aug 2025
... precise control of diffusion in complex, time-varying environments.
Edit

Google’s new diffusion AI agent mimics human writing to improve enterprise research

Venture Beat 06 Aug 2025
A diffusion model inspired by the human process of drafting, searching for information, and making iterative revisions.Read More ....
Edit

Diffuse Large B-Cell Lymphoma Pipeline Outlook Report 2025: Key 70+ Companies and Breakthrough Therapies Shaping ...

GetNews 06 Aug 2025
DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insights 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape.
Edit

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

PR Newswire 06 Aug 2025
"For the first time, we have an FDA-approved therapy for patients with recurrent H3 K27M-mutant diffuse midline glioma ... New progress in the treatment of diffuse midline glioma with H3K27M alteration. Heliyon ... Diffuse Midline Glioma.
×